Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1994 Apr;47(4):309–312. doi: 10.1136/jcp.47.4.309

Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy.

A M Jackson 1, A B Alexandroff 1, M McIntyre 1, K Esuvaranathan 1, K James 1, G D Chisholm 1
PMCID: PMC501932  PMID: 7913098

Abstract

AIMS--To determine the expression of intercellular adhesion molecule 1 and 2 (ICAM 1 and 2) in transitional cell carcinoma cells before and after immunotherapy with Calmette-Guérin bacillus (BCG). METHODS--Frozen sections from 22 untreated bladder carcinomas were immunohistochemically examined with monoclonal antibodies to ICAM 1 and 2. Urinary cytospin slides were made for six patients for each of the six clinical instillations which constitute a therapeutic course. These slides were also stained for ICAM 1 and for leucocyte function associated antigen 1 (LFA 1). RESULTS--Bladder cancer cells did not essentially express either ICAM 1 or 2, but cells in the stromal areas surrounding tumour expressed both these antigens. After repeated instillations of BCG organisms ICAM 1 positive normal and neoplastic epithelial cells were observed in the urine. Cells obtained from the first three instillations expressed lower densities of ICAM 1 than those from the later instillations. Many neutrophils expressing LFA-1 and some lymphocytes were also noted in the cytospin slides and some of these were conjugated to tumour cells expressing ICAM 1. Six months after treatment a single maintenance dose of BCG induced ICAM 1 expression. CONCLUSION--Untreated superficial bladder carcinoma cells do not express ICAM 1 or 2, but these important immunological molecules were expressed in the stromal areas of tissue. Importantly, neoplastic cells in the urine expressed ICAM 1 after immunotherapy. This molecule can render bladder tumour cells vulnerable to non-antigen specific cytotoxicity mediated by activated lymphocytes.

Full text

PDF
311

Images in this article

311Image
on p.311
311Image
on p.311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker J. C., Dummer R., Hartmann A. A., Burg G., Schmidt R. E. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol. 1991 Dec 15;147(12):4398–4401. [PubMed] [Google Scholar]
  2. Böhle A., Nowc C., Ulmer A. J., Musehold J., Gerdes J., Hofstetter A. G., Flad H. D. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J Urol. 1990 Jul;144(1):59–64. doi: 10.1016/s0022-5347(17)39366-7. [DOI] [PubMed] [Google Scholar]
  3. Dransfield I., Cabañas C., Barrett J., Hogg N. Interaction of leukocyte integrins with ligand is necessary but not sufficient for function. J Cell Biol. 1992 Mar;116(6):1527–1535. doi: 10.1083/jcb.116.6.1527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dransfield I., Cabañas C., Craig A., Hogg N. Divalent cation regulation of the function of the leukocyte integrin LFA-1. J Cell Biol. 1992 Jan;116(1):219–226. doi: 10.1083/jcb.116.1.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dustin M. L., Springer T. A. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 1988 Jul;107(1):321–331. doi: 10.1083/jcb.107.1.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Haaff E. O., Catalona W. J., Ratliff T. L. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol. 1986 Oct;136(4):970–974. doi: 10.1016/s0022-5347(17)45142-1. [DOI] [PubMed] [Google Scholar]
  7. Hawkyard S. J., Jackson A. M., James K., Prescott S., Smyth J. F., Chisholm G. D. The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol. 1992 May;147(5):1399–1403. doi: 10.1016/s0022-5347(17)37582-1. [DOI] [PubMed] [Google Scholar]
  8. Hawkyard S., James K., Prescott S., Jackson A. M., Ritchie A. W., Smyth J. F., Chisholm G. D. The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J Urol. 1991 May;145(5):1078–1081. doi: 10.1016/s0022-5347(17)38538-5. [DOI] [PubMed] [Google Scholar]
  9. Jackson A. M., Alexandroff A. B., Lappin M. B., Esuvaranathan K., James K., Chisholm G. D. Control of leucocyte function-associated antigen-1-dependent cellular conjugation by divalent cations. Immunology. 1994 Jan;81(1):120–126. [PMC free article] [PubMed] [Google Scholar]
  10. Jackson A. M., Alexandrov A. B., Gribben S. C., Esuvarnathan K., James K. Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer. 1993 Dec 2;55(6):921–925. doi: 10.1002/ijc.2910550608. [DOI] [PubMed] [Google Scholar]
  11. Jackson A. M., Alexandrov A. B., Prescott S., James K., Chisholm G. D. Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumour necrosis factor-alpha. J Urol. 1992 Nov;148(5):1583–1586. doi: 10.1016/s0022-5347(17)36974-4. [DOI] [PubMed] [Google Scholar]
  12. Jackson A. M., Alexandrov A. B., Prescott S., James K., Chisholm G. D. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology. 1992 Jun;76(2):286–291. [PMC free article] [PubMed] [Google Scholar]
  13. Jackson A. M., Hawkyard S. J., Prescott S., Ritchie A. W., James K., Chisholm G. D. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. J Urol. 1992 Jan;147(1):207–211. doi: 10.1016/s0022-5347(17)37198-7. [DOI] [PubMed] [Google Scholar]
  14. Jackson A. M., Prescott S., Hawkyard S. J., James K., Chisholm G. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol Immunother. 1993;36(1):25–30. doi: 10.1007/BF01789127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lamm D. L., van der Meijden P. M., Morales A., Brosman S. A., Catalona W. J., Herr H. W., Soloway M. S., Steg A., Debruyne F. M. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992 Mar;147(3):596–600. doi: 10.1016/s0022-5347(17)37316-0. [DOI] [PubMed] [Google Scholar]
  16. Mackay C. R., Imhof B. A. Cell adhesion in the immune system. Immunol Today. 1993 Mar;14(3):99–102. doi: 10.1016/0167-5699(93)90205-Y. [DOI] [PubMed] [Google Scholar]
  17. Natali P., Nicotra M. R., Cavaliere R., Bigotti A., Romano G., Temponi M., Ferrone S. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 1990 Feb 15;50(4):1271–1278. [PubMed] [Google Scholar]
  18. Prescott S., James K., Busuttil A., Hargreave T. B., Chisholm G. D., Smyth J. F. HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol. 1989 Mar;63(3):264–269. doi: 10.1111/j.1464-410x.1989.tb05187.x. [DOI] [PubMed] [Google Scholar]
  19. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 1990 Nov;144(5):1248–1251. doi: 10.1016/s0022-5347(17)39713-6. [DOI] [PubMed] [Google Scholar]
  20. Ratliff T. L., Gillen D., Catalona W. J. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987 Jan;137(1):155–158. doi: 10.1016/s0022-5347(17)43909-7. [DOI] [PubMed] [Google Scholar]
  21. Staunton D. E., Merluzzi V. J., Rothlein R., Barton R., Marlin S. D., Springer T. A. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell. 1989 Mar 10;56(5):849–853. doi: 10.1016/0092-8674(89)90689-2. [DOI] [PubMed] [Google Scholar]
  22. Tsujisaki M., Imai K., Hirata H., Hanzawa Y., Masuya J., Nakano T., Sugiyama T., Matsui M., Hinoda Y., Yachi A. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol. 1991 Jul;85(1):3–8. doi: 10.1111/j.1365-2249.1991.tb05673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Van Seventer G. A., Shimizu Y., Horgan K. J., Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol. 1990 Jun 15;144(12):4579–4586. [PubMed] [Google Scholar]
  24. de Fougerolles A. R., Springer T. A. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med. 1992 Jan 1;175(1):185–190. doi: 10.1084/jem.175.1.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. el-Demiry M. I., Smith G., Ritchie A. W., James K., Cumming J. A., Hargreave T. B., Chisholm G. D. Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol. 1987 Dec;60(6):543–548. doi: 10.1111/j.1464-410x.1987.tb05039.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES